| Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide. | |
| | |
MedLine Citation:
|
PMID: 20133507 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The once-daily human glucagon-like peptide-1 (GLP-1) analog, liraglutide, was recently shown to provide improved glycemic control in subjects with type 2 diabetes (T2D) compared with exenatide. The aim of this work is to estimate the population pharmacokinetics of liraglutide and make a comparison to the pharmacokinetic profile of exenatide. Pharmacokinetic data from 5 published studies of subcutaneous and intravenous administration of liraglutide to healthy volunteers (HV) and subjects with T2D were used to develop a population pharmacokinetic model in NONMEM. Exenatide data came from a published study in T2D. Liraglutide pharmacokinetics were adequately described using a 1-compartment model with sequential zero- and first-order absorption. The pharmacokinetic profile of once-daily liraglutide showed considerably smaller peak-to-trough fluctuations compared with twice-daily exenatide. A small difference in the estimates of absorption parameters was found between HV and subjects with T2D but was not clinically relevant. It was concluded that pharmacokinetic profiles estimated by modeling showed that liraglutide has pharmacokinetic properties consistent with once-daily dosing in humans and provides better pharmacokinetic coverage in comparison with twice-daily exenatide. Furthermore, no clinically relevant differences were found in liraglutide pharmacokinetics between HV and subjects with T2D. |
| | |
Authors:
|
Estelle Watson; Daniël M Jonker; Lisbeth V Jacobsen; Steen H Ingwersen |
Related Documents
:
|
8188737 - Limited-sampling models for anticancer agents. 1302767 - Evaluation of bayesian estimation in comparison to nonmem for population pharmacokineti... 17681967 - Estimation of the plasma effect-site equilibration rate constant (ke0) of rocuronium by... 17825517 - The thermodynamic dissociation constants of four non-steroidal anti-inflammatory drugs ... 7482537 - Toxicokinetics of topical sulfur mustard penetration, disposition, and vascular toxicit... 18532857 - Injury tolerance and moment response of the knee joint to combined valgus bending and s... |
Publication Detail:
|
Type: Comparative Study; Journal Article Date: 2010-02-04 |
Journal Detail:
|
Title: Journal of clinical pharmacology Volume: 50 ISSN: 1552-4604 ISO Abbreviation: J Clin Pharmacol Publication Date: 2010 Aug |
Date Detail:
|
Created Date: 2010-07-20 Completed Date: 2010-11-08 Revised Date: 2013-05-13 |
Medline Journal Info:
|
Nlm Unique ID: 0366372 Medline TA: J Clin Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 886-94 Citation Subset: IM |
Affiliation:
|
Novo Nordisk A/S, Novo Alle, Postbox 1000, DK-2880 Bagsvaerd, Denmark. ellw@novonordisk.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Trials as Topic Diabetes Mellitus, Type 2 / drug therapy*, metabolism Drug Administration Schedule Glucagon-Like Peptide 1 / administration & dosage, analogs & derivatives*, pharmacokinetics Humans Hypoglycemic Agents / administration & dosage, pharmacokinetics* Metabolic Clearance Rate Models, Biological* Peptides / administration & dosage, pharmacokinetics* Venoms / administration & dosage, pharmacokinetics* |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 0/Peptides; 0/Venoms; 141732-76-5/exenatide; 839I73S42A/liraglutide; 89750-14-1/Glucagon-Like Peptide 1 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Families' and professional caregivers' views of using advanced technology to track people with demen...
Next Document: Lack of Racial Differences in the Pharmacokinetics of Subcutaneous Golimumab in Healthy Japanese and...